The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Inflammatory cortical demyelination in early multiple sclerosis.
Open accessAbstract
BACKGROUND: Cortical disease has emerged as a critical aspect of the pathogenesis of multiple sclerosis, being associated with disease progression and cognitive impairment. Most studies of cortical lesions have focused on autopsy findings in patients with long-standing, chronic, progressive multiple sclerosis, and the noninflammatory nature of these lesions has been emphasized. Magnetic resonance imaging studies indicate that cortical damage occurs early in the disease. METHODS: We evaluated the prevalence and character of demyelinating cortical lesions in patients with multiple sclerosis. Cortical tissues were obtained in passing during biopsy sampling of white-matter lesions. In most cases, biopsy was done with the use of stereotactic procedures to diagnose suspected tumors. Patients with sufficient cortex (138 of 563 patients screened) were evaluated for cortical demyelination. Using immunohistochemistry, we characterized cortical lesions with respect to demyelinating activity, inflammatory infiltrates, the presence of meningeal inflammation, and a topographic association between cortical demyelination and meningeal inflammation. Diagnoses were ascertained in a subgroup of 77 patients (56%) at the last follow-up visit (at a median of 3.5 years). RESULTS: Cortical demyelination was present in 53 patients (38%) (104 lesions and 222 tissue blocks) and was absent in 85 patients (121 tissue blocks). Twenty-five patients with cortical demyelination had definite multiple sclerosis (81% of 31 patients who underwent long-term follow-up), as did 33 patients without cortical demyelination (72% of 46 patients who underwent long-term follow-up). In representative tissues, 58 of 71 lesions (82%) showed CD3+ T-cell infiltrates, and 32 of 78 lesions (41%) showed macrophage-associated demyelination. Meningeal inflammation was topographically associated with cortical demyelination in patients who had sufficient meningeal tissue for study. CONCLUSIONS: In this cohort of patients with early-stage multiple sclerosis, cortical demyelinating lesions were frequent, inflammatory, and strongly associated with meningeal inflammation. (Funded by the National Multiple Sclerosis Society and the National Institutes of Health.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“This may well reflect the greater microglia and astrocyte activity in the white matter; pure cortical lesions in post-mortem tissues show little or no inflammation (Bo et al., 2004; Brink et al., 2005; van Horssen et al., 2007), although early lesions have been associated with prominent microglial activation (Lucchinetti et al., 2011).”
From A quantitative neuropathological assessment of translocator protein expression in multiple sclerosis (2019) · cites this paper as Lucchinetti et al., 2011
In the citing paper
“Biopsies taken from early MS patients with cortical demyelination were more likely to have leptomeningeal inflammation, consisting of effector T cells and IgA B cells infiltrates, than those without cortical demyelination.”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Lucchinetti et al., 2011
In the citing paper
“The leptomeninges are now recognized as a key player in multiple sclerosis (MS), an inflammatory CNS autoimmune disorder characterized by axon demyelination”
From Living on the Edge of the CNS: Meninges Cell Diversity in Health and Disease (2021) · cites this paper as Lucchinetti et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Revised diagnostic criteria for neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Pittock, S. J., Lucchinetti, C. F., & Weinshenker, B. G. (2006) · Neurology · doi:10.1212/01.wnl.0000216139.44259.74 · Cited by 2,568
Self-citationCortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Self-citationMagliozzi, R., Howell, O. W., Vora, A., Serafini, B., Nicholas, R. S., Puopolo, M., Reynolds, R., & Aloisi, F. (2006) · Brain · doi:10.1093/brain/awm038 · Cited by 1,486
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., & Aloisi, F. (2004) · Brain Pathology · doi:10.1111/j.1750-3639.2004.tb00049.x · Cited by 1,208
Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., & Sallusto, F. (2009) · Nature Immunology · doi:10.1038/ni.1716 · Cited by 1,206
Cortical lesions in multiple sclerosis
Kidd, D., Barkhof, F., McConnell, R., Algra, P. R., Allen, I. V., & Revesz, T. (1999) · Brain · doi:10.1093/brain/122.1.17 · Cited by 766
Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients
Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D., & Mørk, S. J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.7.723 · Cited by 757
Research works printed but not linked: 1
- Tardif CL, 2010, Med Image Comput Assist Interv, 13, 181
Cited by
Sorted by citations
Items 301–400 of 1,000
Ectopic lymphoid follicles in progressive multiple sclerosis: From patients to animal models
Zhan, J., Kipp, M., Han, W., & Kaddatz, H. (2021) · Immunology · doi:10.1111/imm.13395 · Cited by 49
B Cells and Autoantibodies in Multiple Sclerosis
Pröbstel, A., Sanderson, N., & Derfuss, T. J. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160716576 · Cited by 50
Gray Matter Is Targeted in First-Attack Multiple Sclerosis
Schutzer, S. E., Angel, T. E., Liu, T., Schepmoes, A., Xie, F., Bergquist, J., Vécsei, L., Zádori, D., Camp, D., Holland, B. K., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066117 · Cited by 49
Predictors of disability worsening in clinically isolated syndrome
Jokubaitis, V., Spelman, T. D., Kalinčík, T., Izquierdo, G., Grand’Maison, F., Duquette, P., Girard, M., Lugaresi, A., Grammond, P., Hupperts, R., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.187 · Cited by 49
Zivadinov, R., Ramasamy, D. P., Hagemeier, J., Kolb, C., Bergsland, N., Schweser, F., Dwyer, M. G., Weinstock‐Guttman, B., & Hojnacki, D. W. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5541 · Cited by 49
MRI of cortical lesions and its use in studying their role in MS pathogenesis and disease course
Magliozzi, R., Reynolds, R., & Calabrese, M. (2018) · Brain Pathology · doi:10.1111/bpa.12642 · Cited by 51
Synaptic Loss in Multiple Sclerosis: A Systematic Review of Human Post-mortem Studies
Möck, E. E. A., Honkonen, E., & Airas, L. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.782599 · Cited by 49
C1q and central nervous system disorders
Zhang, W., Chen, Y., & Pei, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145649 · Cited by 49
Rocca, M. A., Preziosa, P., Mesaroš, Š., Pagani, E., Dackovic, J. R., Stošić-Opinćal, T., Drulovic, J. S., & Filippi, M. (2015) · Radiology · doi:10.1148/radiol.2015150532 · Cited by 48
Li, S., Clements, R. J., Sulak, M. A., Gregory, R. B., Freeman, E. J., & McDonough, J. A. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1151-8 · Cited by 48
Haugen, M., Frederiksen, J. L., & Degn, M. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.05.010 · Cited by 48
Ectopic Lymphoid Follicles in Multiple Sclerosis: Centers for Disease Control?
Negron, A., Stüve, O., & Forsthuber, T. G. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.607766 · Cited by 47
Childhood inflammatory brain diseases: pathogenesis, diagnosis and therapy
Twilt, M., & Benseler, S. M. (2013) · Rheumatology · doi:10.1093/rheumatology/ket398 · Cited by 47
Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS
Zivadinov, R., Cerza, N., Hagemeier, J., Carl, E. M., Badgett, D., Ramasamy, D. P., Weinstock‐Guttman, B., & Ramanathan, M. K. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000190 · Cited by 48
Neuropilin-1 modulates interferon-γ-stimulated signaling in brain microvascular endothelial cells
Wang, Y., Cao, Y., Mangalam, A. K., Guo, Y. X., LaFrance‐Corey, R. G., Gamez, J. D., Atanga, P. A., Clarkson, B. D. S., Zhang, Y., Wang, E., et al. (2016) · Journal of Cell Science · doi:10.1242/jcs.190702 · Cited by 47
Self-citationEvonuk, K. S., Doyle, R. E., Moseley, C. E., Thornell, I. M., Adler, K., Bingaman, A. M., Bevensee, M. O., Weaver, C. T., Min, B., & DeSilva, T. M. (2020) · Science Advances · doi:10.1126/sciadv.aax5936 · Cited by 49
Altered astrocytic function in experimental neuroinflammation and multiple sclerosis
das Neves, S. P., Sousa, J. C., Sousa, N., Cerqueira, J., & Marques, F. (2020) · Glia · doi:10.1002/glia.23940 · Cited by 49
Morgan, B. P., Gommerman, J. L., & Ramaglia, V. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.600656 · Cited by 51
García‐Merino, A. (2021) · Cells · doi:10.3390/cells10102560 · Cited by 47
Favaretto, A., Poggiali, D., Lazzarotto, A., Rolma, G., Causin, F., & Gallo, P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127805 · Cited by 49
The Spectrum of Neuromyelitis Optica (NMO) in Childhood
Tillema, J., & McKeon, A. B. (2012) · Journal of Child Neurology · doi:10.1177/0883073812451495 · Cited by 47
Primary Progressive Multiple Sclerosis: Putting Together the Puzzle
Abdelhak, A., Weber, M. S., & Tumani, H. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00234 · Cited by 46
Mitsdoerffer, M., Liberto, G. D., Dötsch, S., Sie, C., Wagner, I., Pfaller, M., Kreutzfeldt, M., Fräßle, S. P., Aly, L., Knier, B., et al. (2021) · Brain · doi:10.1093/brain/awab093 · Cited by 49
The brain cytokine orchestra in multiple sclerosis: from neuroinflammation to synaptopathology
Amoriello, R., Memo, C., Ballerini, L., & Ballerini, C. (2024) · Molecular Brain · doi:10.1186/s13041-024-01077-7 · Cited by 47
Multiple sclerosis treatment and infectious issues: update 2013
Winkelmann, A., Loebermann, M., Reisinger, E. C., & Zettl, U. K. (2013) · Clinical & Experimental Immunology · doi:10.1111/cei.12226 · Cited by 45
Jurcoane, A., Wagner, M., Schmidt, C. G., Mayer, C., Gracien, R., Hirschmann, M. M., Deichmann, R., Volz, S., Ziemann, U., & Hattingen, E. (2013) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.24107 · Cited by 45
Jukkola, P. I., Guerrero, T., Gray, V., & Gu, C. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-70 · Cited by 49
Brana, C., Frossard, M., Gobert, R. P., Martinier, N., Boschert, U., & Seabrook, T. J. (2013) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12048 · Cited by 45
Beyond focal cortical lesions in MS
Louapre, C., Govindarajan, S. T., Giannì, C., Langkammer, C., Sloane, J. A., Kinkel, R. P., & Mainero, C. (2015) · Neurology · doi:10.1212/wnl.0000000000002106 · Cited by 45
Anti-CD20 monoclonal antibodies in multiple sclerosis
Moreno‐Torres, I., & García‐Merino, A. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1245616 · Cited by 45
Puthenparampil, M., Federle, L., Poggiali, D., Miante, S., Signori, A., Pilotto, E., Rinaldi, F., Perini, P., Sormani, M. P., Midena, E., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183957 · Cited by 45
Role of lipoic acid in multiple sclerosis
Xie, H., Yang, X., Cao, Y., Long, X., Shang, H., & Jia, Z. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13793 · Cited by 46
Quantitative Magnetic Resonance Imaging of Cortical Multiple Sclerosis Pathology
Tardif, C. L., Bedell, B. J., Eskildsen, S. F., Collins, D. L., & Pike, G. B. (2012) · Multiple Sclerosis International · doi:10.1155/2012/742018 · Cited by 45
Rodriguez, E. G., Wegner, C., Kreutzfeldt, M., Neid, K., Thal, D. R., Jürgens, T., Brück, W., Stadelmann, C., & Merkler, D. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1260-8 · Cited by 44
Self-citationExpression of Translocator Protein and [18F]-GE180 Ligand Uptake in Multiple Sclerosis Animal Models
Nack, A., Brendel, M., Nedelcu, J., Daerr, M., Nyamoya, S., Beyer, C., Focke, C., Deussing, M., Hoornaert, C., Ponsaerts, P., et al. (2019) · Cells · doi:10.3390/cells8020094 · Cited by 43
Imaging cortical multiple sclerosis lesions with ultra-high field MRI
Madsen, M. A. J., Wiggermann, V., Bramow, S., Christensen, J. R., Sellebjerg, F. T., & Siebner, H. R. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102847 · Cited by 45
From pathology to MRI and back: Clinically relevant biomarkers of multiple sclerosis lesions
Kolb, H., Al‐Louzi, O., Beck, E., Sati, P., Absinta, M., & Reich, D. S. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.103194 · Cited by 44
Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations
Honce, J. M. (2013) · Multiple Sclerosis International · doi:10.1155/2013/627870 · Cited by 46
Natalizumab strongly suppresses cortical pathology in relapsing–remitting multiple sclerosis
Rinaldi, F., Calabrese, M., Seppi, D., Puthenparampil, M., de Perini, P., & Gallo, P. (2012) · Multiple Sclerosis Journal · doi:10.1177/1352458512447704 · Cited by 43
Autoantibodies to Non-myelin Antigens as Contributors to the Pathogenesis of Multiple Sclerosis
Levin, M. C. (2013) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000148 · Cited by 43
Toll-like receptor signalling as a cannabinoid target in Multiple Sclerosis
Fitzpatrick, J.-M., & Downer, E. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.009 · Cited by 43
Microglia: The Missing Link to Decipher and Therapeutically Control MS Progression?
Geladaris, A., Häusler, D., & Weber, M. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073461 · Cited by 44
Effects of non-invasive brain stimulation in multiple sclerosis: systematic review and meta-analysis
Kan, R. L. D., Xu, G. X. J., Shu, K. T., Lai, F. H., Kranz, G., & Kranz, G. S. (2022) · Therapeutic Advances in Chronic Disease · doi:10.1177/20406223211069198 · Cited by 43
Spreading Depression Transiently Disrupts Myelin via Interferon-Gamma Signaling
Pusic, A. D., Mitchell, H. M., Kunkler, P. E., Klauer, N., & Kraig, R. P. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2014.12.001 · Cited by 42
Lymphotoxin-alpha expression in the meninges causes lymphoid tissue formation and neurodegeneration
Bates, R. E. J., Browne, E., Schalks, R., Jacobs, H., Tan, L. Y., Parekh, P., Magliozzi, R., Calabrese, M., Mazarakis, N. D., & Reynolds, R. (2022) · Brain · doi:10.1093/brain/awac232 · Cited by 42
Miljković, D. M., Blaževski, J., Petković, F., Djedović, N., Momčilović, M. B., Stanisavljević, S., Jevtić, B., Stojković, M. M., & Spasojević, I. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402302 · Cited by 42
Filley, C. M. (2012) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612454323 · Cited by 45
Daclizumab (anti-CD25) in multiple sclerosis
Pfender, N., & Martinꝉ, R. (2014) · Experimental Neurology · doi:10.1016/j.expneurol.2014.04.015 · Cited by 44
Emerging Approaches for Validating and Managing Multiple Sclerosis Relapse
Mills, E. A., Mirza, A., & Mao‐Draayer, Y. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00116 · Cited by 41
Neurodegeneration in multiple sclerosis is a process separate from inflammation: Yes
Louapre, C., & Lubetzki, C. (2015) · Multiple Sclerosis Journal · doi:10.1177/1352458515587598 · Cited by 41
Periventricular lesions correlate with cortical thinning in multiple sclerosis
Jehna, M., Pirpamer, L., Khalil, M., Fuchs, S., Ropele, S., Langkammer, C., Pichler, A., Stulnig, F., Deutschmann, H., Fazekas, F., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24461 · Cited by 41
A practical review of the neuropathology and neuroimaging of multiple sclerosis
Matthews, P. M., Roncaroli, F., Waldman, A. D., Sormani, M. P., Stefano, N. D., Giovannoni, G., & Reynolds, R. (2016) · Practical Neurology · doi:10.1136/practneurol-2016-001381 · Cited by 46
Correlation between cortical lesions and cognitive impairment in multiple sclerosis
Curti, E., Graziuso, S., Tsantes, E., Crisi, G., & Granella, F. (2018) · Brain and Behavior · doi:10.1002/brb3.955 · Cited by 41
Gao, F., Yin, X., Edden, R. A. E., Evans, A. C., Xu, J., Cao, G., Li, H., Li, M., Zhao, B., Wang, J., et al. (2018) · Hippocampus · doi:10.1002/hipo.23001 · Cited by 42
Axonal and neuronal degeneration in myelin diseases
Ohno, N., & Ikenaka, K. (2018) · Neuroscience Research · doi:10.1016/j.neures.2018.08.013 · Cited by 42
Gadolinium and Multiple Sclerosis: Vessels, Barriers of the Brain, and Glymphatics
Saade, C., Bou‐Fakhredin, R., Yousem, D. M., Asmar, K., Naffaa, L. N., & El‐Merhi, F. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5773 · Cited by 48
IL‐2mAb reduces demyelination after focal cerebral ischemia by suppressing CD8+ T cells
Zhou, Y., Wang, X., Tang, D., Li, Y., Jiao, Y., Gan, Y., Hu, X., Yang, L., Yu, W., Stetler, R. A., et al. (2018) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13084 · Cited by 41
Bergsland, N., Ramasamy, D. P., Tavazzi, E., Hojnacki, D. W., Weinstock‐Guttman, B., & Zivadinov, R. (2019) · American Journal of Neuroradiology · doi:10.3174/ajnr.a6011 · Cited by 41
Voskuhl, R. R., & MacKenzie‐Graham, A. J. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1024058 · Cited by 45
The influence of HLA‐DRB1*15 on motor cortical pathology in multiple sclerosis
Yates, R. L., Esiri, M. M., Palace, J. A., Mittal, A., & DeLuca, G. C. (2014) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12165 · Cited by 41
Prins, M., Dutta, R., Baselmans, B. M. L., Brevé, J. J. P., Bol, J. G. J. M., Deckard, S. A., van der Valk, P., Amor, S., Trapp, B. D., de Vries, H. E., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0098-6 · Cited by 41
Caulfield, M. E., Hatfield, J. K., & Brown, M. A. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.12.009 · Cited by 40
Mast cell inflammasome activity in the meninges regulates EAE disease severity
Russi, A. E., Caulfield, M. E., & Brown, M. A. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.04.009 · Cited by 41
Immune reconstitution therapy (IRT) in multiple sclerosis: the rationale
Karussis, D. M., & Petrou, P. (2018) · Immunologic Research · doi:10.1007/s12026-018-9032-5 · Cited by 42
Role of Peripheral Immune Cells in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Dhaiban, S., Al‐Ani, M., Elemam, N. M., Al-Aawad, M. H., Al-Rawi, Z., & Maghazachi, A. A. (2021) · Sci · doi:10.3390/sci3010012 · Cited by 40
7 T imaging reveals a gradient in spinal cord lesion distribution in multiple sclerosis
Ouellette, R., Treaba, C. A., Granberg, T., Herranz, E., Barletta, V. T., Mehndiratta, A., Leener, B. D., Tauhid, S., Yousuf, F., Dupont, S. M., et al. (2020) · Brain · doi:10.1093/brain/awaa249 · Cited by 41
Torres, J. B., Roodselaar, J., Sealey, M. A., Ziehn, M. O., Bigaud, M., Kneuer, R., Leppert, D., Weckbecker, G., Cornelissen, B. T., & Anthony, D. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.814064 · Cited by 41
Blakely, P. K., Hussain, S., Carlin, L. E., & Irani, D. N. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00344 · Cited by 42
Multiple sclerosis: Immunopathological heterogeneity and its implications
Engelhardt, B., Comabella, M., & Chan, A. (2022) · European Journal of Immunology · doi:10.1002/eji.202149757 · Cited by 42
Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis
Sellebjerg, F. T., Cadavid, D., Steiner, D., Villar, L. M., Reynolds, R., & Mikol, D. D. (2015) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285615615257 · Cited by 45
Jonas, S. N., Izbudak, I., Frazier, A. A., & Harrison, D. M. (2018) · American Journal of Neuroradiology · doi:10.3174/ajnr.a5796 · Cited by 39
Leptomeningeal inflammation in multiple sclerosis: Insights from animal and human studies
Wicken, C., Nguyen, J. V., Karna, R., & Bhargava, P. (2018) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2018.09.025 · Cited by 40
Beck, E., Gai, N., Filippini, S., Maranzano, J., Nair, G., & Reich, D. S. (2020) · Investigative Radiology · doi:10.1097/rli.0000000000000698 · Cited by 39
Lafosse, J. M., Mitchell, S. M., Corboy, J. R., & Filley, C. M. (2013) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617713000957 · Cited by 38
Jonas, A., Thiem, S., Kuhlmann, T., Wagener, R., Aszódi, A., Nowell, C. J., Hagemeier, K., Laverick, L., Perreau, V. M., Jokubaitis, V., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci71385 · Cited by 38
Edwards, K. R., Goyal, J., Plavina, T., Czerkowicz, J., Goelz, S. E., Ranger, A. M., Cadavid, D., & Browning, J. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081007 · Cited by 37
The potential role of epigenetic modifications in the heritability of multiple sclerosis
Zhou, Y., Simpson, S., Holloway, A. F., Charlesworth, J., van der Mei, I. A. F., & Taylor, B. V. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514520911 · Cited by 37
Remyelination After Cuprizone-Induced Demyelination Is Accelerated in Juvenile Mice
Pfeifenbring, S., Nessler, S., Wegner, C., Stadelmann, C., & Brück, W. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000214 · Cited by 39
Self-citationLive Imaging of Immune Responses in Experimental Models of Multiple Sclerosis
Rossi, B., & Constantin, G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00506 · Cited by 39
Multifaceted Involvement of Microglia in Gray Matter Pathology in Multiple Sclerosis
Tsouki, F., & Williams, A. (2021) · Stem Cells · doi:10.1002/stem.3374 · Cited by 39
Tertiary Lymphoid Structures in the Central Nervous System: Implications for Glioblastoma
van de Walle, T., Vaccaro, A., Ramachandran, M., Pietilä, I., Essand, M., & Dimberg, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.724739 · Cited by 38
CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis
Marastoni, D., Magliozzi, R., Bolzan, A., Pisani, A. I., Rossi, S., Crescenzo, F., Montemezzi, S., Pizzini, F. B., & Calabrese, M. (2021) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000001083 · Cited by 39
Prins, M., Eriksson, C., Wierinckx, A., Bol, J. G. J. M., Binnekade, R., Tilders, F. J. H., & van Dam, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083835 · Cited by 37
Cook, S. D., Dhib-Jalbut, S. S., Dowling, P. C., Durelli, L., Ford, C. C., Giovannoni, G., Halper, J., Harris, C. J., Herbert, J., Li, D., et al. (2012) · International Journal of MS Care · doi:10.7224/1537-2073-14.3.105 · Cited by 39
Self-citationGeladaris, A., Häusser‐Kinzel, S., Pretzsch, R., Nissimov, N., Lehmann‐Horn, K., Häusler, D., & Weber, M. S. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02552-6 · Cited by 36
Liu, Y., Xie, T., Yong He, A., Duan, Y., Huang, J., Ren, Z., Gong, G., Wang, J., Ye, J., Dong, H., et al. (2014) · European Radiology · doi:10.1007/s00330-014-3239-1 · Cited by 36
FLAIR2: A Combination of FLAIR and T2 for Improved MS Lesion Detection
Wiggermann, V., Hernández‐Torres, E., Traboulsee, A. L., Li, D. K. B., & Rauscher, A. (2015) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4514 · Cited by 36
Worsening of disability caused by relapses in multiple sclerosis: A different approach
Koch‐Henriksen, N., Thygesen, L. C., Sørensen, P. S., & Magyari, M. (2019) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2019.04.017 · Cited by 36
Solana, E., Martínez‐Heras, E., Montal, V., Vilaplana, E., López-Soley, E., Raduà, J., Solà‐Valls, N., Montejo, C., Blanco, Y., Pulido-Valdeolivas, I., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-96132-x · Cited by 38
Contribution of B cells to cortical damage in multiple sclerosis
Bhargava, P., Hartung, H.-P., & Calabresi, P. A. (2022) · Brain · doi:10.1093/brain/awac233 · Cited by 36
Multiple Sclerosis Pathogenesis and Updates in Targeted Therapeutic Approaches
Vasileiou, E. S., & Fitzgerald, K. C. (2023) · Current Allergy and Asthma Reports · doi:10.1007/s11882-023-01102-0 · Cited by 41
Wang, A. A., Luessi, F., Neziraj, T., Pössnecker, E., Zuo, M., Engel, S., Hanuscheck, N., Florescu, A., Bugbee, E., Xianjie, I., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0295 · Cited by 37
Cortical imaging in multiple sclerosis
Daams, M., Geurts, J. J. G., & Barkhof, F. (2013) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328362a864 · Cited by 35
Identifying autoantigens in demyelinating diseases
Derfuss, T. J., & Meinl, E. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283533a64 · Cited by 35
The window of opportunity for treatment of progressive multiple sclerosis
Sørensen, P. S., Fox, R. J., & Comi, G. (2020) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000811 · Cited by 35
Imaging Mechanisms of Disease Progression in Multiple Sclerosis: Beyond Brain Atrophy
Bagnato, F. R., Gauthier, S. A., Laule, C., Moore, G. R. W., Bove, R. M., Cai, Z., Cohen‐Adad, J., Harrison, D. M., Klawiter, E. C., Morrow, S. A., et al. (2020) · Journal of Neuroimaging · doi:10.1111/jon.12700 · Cited by 37
CSF parvalbumin levels reflect interneuron loss linked with cortical pathology in multiple sclerosis
Magliozzi, R., Pitteri, M., Ziccardi, S., Pisani, A. I., Montibeller, L., Marastoni, D., Rossi, S., Mazziotti, V., Guandalini, M., Dapor, C., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51298 · Cited by 35
T-cell surveillance of the human brain in health and multiple sclerosis
Smolders, J., van Luijn, M. M., Hsiao, C., & Hamann, J. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00926-8 · Cited by 37
Breaching Brain Barriers: B Cell Migration in Multiple Sclerosis
Rodriguez-Mogeda, C., Rodríguez‐Lorenzo, S., Attia, J. V. D., van Horssen, J., Witte, M. E., & de Vries, H. E. (2022) · Biomolecules · doi:10.3390/biom12060800 · Cited by 36
Toward identifying key mechanisms of progression in multiple sclerosis
Husseini, L., Geladaris, A., & Weber, M. S. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.11.005 · Cited by 35
Metadata
- Authors
- Lucchinetti, C. F., Popescu, B. F. G., Bunyan, R. F., Moll, N. M., Roemer, S. F., Lassmann, H., Brück, W., Parisi, J. E., Scheithauer, B. W., Giannini, C., Weigand, S. D., Mandrekar, J., & Ransohoff, R. M.
- Affiliations
- Mayo Clinic (US)
- Cleveland Clinic Research (US)
- Medical University of Vienna (AT)
- Universitätsmedizin Göttingen (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-12-08
- Volume
- 365
- Issue
- 23
- Pages
- 2188-2197
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3282172
- OpenAlex
- W2113948549
- Cited by
- 1,103
- References
- 50
- Citations by year
- 2026: 37 · 2025: 44 · 2024: 69 · 2023: 70 · 2022: 68 · 2021: 104 · 2020: 75 · 2019: 83 · 2018: 64 · 2017: 72 · 2016: 75 · 2015: 84 · 2014: 89 · 2013: 100 · 2012: 67
- FWCI
- 58.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- GoeScholar The Publication Server of the Georg-August-Universität Göttingen (Georg-August-Universität Göttingen) (submittedVersion, cc-by)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- National Multiple Sclerosis Society (RG3185-B-3)
- Multiple Sclerosis Society
- National Institutes of Health (P50NS38667)
- National Institute of Neurological Disorders and Stroke (P50NS38667, P50NS038667, R01NS049577)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Health Sciences › Medicine › Oncology › Polyomavirus and related diseases
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- multiple sclerosis, cortical demyelination, inflammatory demyelination, meningeal inflammation, cortical lesions, early multiple sclerosis, white matter lesions, stereotactic biopsy, disease progression
- MeSH terms
- Biopsy, Cerebral Cortex, Humans, Inflammation, Multiple Sclerosis, Prevalence, Logistic Models, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
